Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients 21-85 years of age~2. Individuals diagnosed with IPF, based on:~   * clinical symptoms consistent with idiopathic pulmonary fibrosis (IPF) of \> 3 months duration, plus~  * histologically diagnosed UIP or diagnostic chest high resolution CT features of UIP, plus~  * negative workup for known causes of UIP~3. Ability to understand a written informed consent form and comply with the requirements of the study.~Exclusion Criteria:~1. Clinical features or known diagnosis of an active infection, including untreated latent tuberculosis~2. Clinical features or known diagnosis of malignancy~3. Known diagnosis of an interstitial lung disease other than IPF including but not limited to sarcoidosis, hypersensitivity pneumonitis, non-specific interstitial pneumonia (NSIP).~4. History of clinically significant environmental exposures known to cause interstitial lung disease (including but not limited to drugs, asbestos, silica, beryllium, radiation, domestic birds, etc).~5. Diagnosis of any connective tissue disease (including but not limited to scleroderma, SLE, rheumatoid arthritis) or vasculitides according to the American College of Rheumatology criteria.~6. Systolic blood pressure \< 100 or \>145 mm Hg or diastolic blood pressure \< 50 or \>90 mmHg~7. Evidence of active infection within 1 week prior to enrollment.~8. Recently started (\<8 weeks prior to baseline visit) or planned cardiopulmonary rehabilitation program before conclusion of the study~9. History of unstable or deteriorating cardiac disease, including but not limited to: myocardial infarction, coronary artery bypass surgery or angioplasty within the past 6 months, congestive heart failure requiring hospitalization within the past 6 months, or uncontrolled arrhythmia~10. History of unstable or deteriorating neurologic disease, including but not limited to: TIAs or stroke~11. Pregnant or lactating females. Females of child bearing potential are required to have a negative serum or urine pregnancy test prior to treatment and agree to practice abstinence or prevent pregnancy by at least a barrier method of birth control.~12. Liver panel above specific limits at screening: Total bilirubin \>1.5-fold upper limit of normal, AST, ALT or alkaline phosphatase \> 3-fold upper limit of normal at screening.~13. Hematology outside of specified limits, WBC \<2,500/ mm3, hematocrit \<30, platelets \<100,000/mm3 at screening.~14. Investigational therapy for any indication within 28 days prior to treatment.~15. Current treatment with drugs that are strong inhibitors of CYP3A4 or P-gp, namely bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, HIV-protease inhibitors (e.g., ritonavir, indinavir), metoclopramide, nicardipine, troleandomycin, verapamil~16. Inability or unwillingness to comply with the requirements for the trial.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).